A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

NCT07175038 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Arterial Hypertension (PAH)
Pulmonary Hypertension, Interstitial Lung Disease

Interventions

DRUG: ROC-101

Sponsor

AllRock Bio, Inc.